Journal
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
Volume 11, Issue 1, Pages 78-98Publisher
HARBORSIDE PRESS
DOI: 10.6004/jnccn.2013.0011
Keywords
-
Categories
Funding
- NCI NIH HHS [P30 CA006973] Funding Source: Medline
- NATIONAL CANCER INSTITUTE [P30CA006973] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Neuroendocrine tumors account for approximately 20% of lung cancers; most (approximate to 15%) are small cell lung cancer (SCLC). These NCCN Clinical Practice Guidelines in Oncology for SCLC focus on extensive-stage SCLC because it occurs more frequently than limited-stage disease. SCLC is highly sensitive to initial therapy; however, most patients eventually die of recurrent disease. In patients with extensive-stage disease, chemotherapy alone can palliate symptoms and prolong survival in most patients; however, long-term survival is rare. Most cases of SCLC are attributable to cigarette smoking; therefore, smoking cessation should be strongly promoted. (JNCCN 2013;11:78-98)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available